Emgality® is the first and only calcitonin gene-related peptide (CGRP) antibody approved with specific doses for adults with migraine and adults with episodic cluster headache1,2
More is possible with Emgality
INDICATIONS
Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.
SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
Emgality is the first and only CGRP antibody approved for both migraine and episodic cluster headache.1,2
Learn more about response rates for migraine or episodic cluster headache
As of 03/02/2020, best-in-class access for the preventive treatment of migraine for patients with migraine, regardless of insurance type1,9a-d
Learn more about coverage for your patients
aSource: Managed Markets Insight & Technology (MMIT), LLC as of 03/2020 and is subject to change without notice. Please contact the plan or state for the most current information.
bBest-in-class access indicates the subcutaneous CGRP antibody injection on prescription drug plans with pharmacy benefit coverage for the most lives at or equivalent to Preferred, Covered, Specialty, or Generic on all commercial and Medicare Part D plans and with preferred status on a state’s Medicaid publicly available Fee-for-Service Medicaid Preferred Drug List (PDL) for the preventive treatment of migraine.2 Does not take into consideration any restrictions set forth by individual plans. Data as of 03/2020.
cThis information is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures.
dEmployers and employer groups may also offer additional benefit designs, which may be different than described.
Emgality comes in an easy-to-use pen for self-administration1,10
Patient- and caregiver-rated experiences with the pen were assessed in an open-label, 12-month study. A total of 84 patients who received once-monthly injections of Emgality 120 mg completed a questionnaire that included ratings of the medication delivery device’s overall ease of use.11
Learn more about dosing
References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0085. 3. Aimovig [Prescribing Information]. Thousand Oaks, CA: Amgen Inc.; 2019. 4. Ajovy [Prescribing Information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2019. 5. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-1088. 6. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. 7. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221. 8. Data on File. Lilly USA, LLC. DOF-GZ-US-0107. 9. Data on File. Lilly USA, LLC. DOF-GZ-US-0114. 10. Data on File. Lilly USA, LLC. DOF-GZ-US-0013. 11. Data on File. Lilly USA, LLC. DOF-GZ-US-0020.